Navigation Links
Cellectis Publishes Its Financial Statement for the First Half of 2010
Date:10/15/2010

PARIS, Oct. 15 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, today published its consolidated financial statement for the half-year ending June 30, 2010: revenues increased 25% over H1 2009, expenditure increased 50% and the company ended the period with euro 38 million in cash reserves.

During the first half of 2010, Cellectis entered into a number of important new agreements (with BASF Plant Science, Boehringer Ingelheim), published data in a peer-reviewed journal on the therapeutic potential of meganucleases in Duchenne muscular dystrophy and launched Cellectis plant sciences. Cellectis was also granted the INPI National Innovation Award for its intellectual property strategy. In addition, Cellectis' research and production tools subsidiary, Cellectis bioresearch, entered into a development and commercial manufacturing agreement with Lonza that establishes a presence for Cellectis in the bioproduction market.

"The figures for this half year reflect our growth strategy," said Andre Choulika, CEO at Cellectis. "Cellectis' staff has doubled in a year and comprises 130 people today, in all entities, compared to 65 in July 2009. This has allowed us to strengthen our position, in all aspects of our business, with highly competent and committed people."

"The capital increase that was made in October 2009 allows us to finance this rapid growth and support our ambitious external growth strategy," added Marc Le Bozec, CFO at Cellectis.

The slide show presenting the half-year results in details is available on http://www.cellectis.com/investors/accounts-and-reports Simplified Income Statement – Financial items are presented according to IFRSFigures in thousands of euros

2010
first 6 months2009
first  6 monthsSales

6 2505 020Other revenue

6336Total revenue6 3135 056Consumables

(1 231)(901)Wages & Salaries

(4 502)(2 908)Other operating expenses

(9 276)(6 752)Tax

(168)(193)Depreciation & Amortization

(139)(221)Total operating expenses(15 316)(10 975)Current operating income/loss(9 003)(5 919)Other non-current income and expenses

4661Operating income (loss)(8 957)(5 858)Financial income

241282Financial expenses

(17)(1)Cost of financing, net225281Income tax

5 2402 810Net operating income (loss)(3 492)(2 767)About CellectisCellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com

Follow Cellectis on Twitter at www.twitter.com/cellectis

DisclaimerThis press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
2. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
3. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
4. Cellectis bioresearch Announces Establishment of Subsidiary in the US
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
8. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
9. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... CRANBURY, N.J. , March 23, 2017 ... pharmaceutical company, announced a major milestone today.  ... meetings with the U.S. Food and Drug ... a clear clinical and regulatory path forward ... compound, CPI-613, in patients with acute myeloid ...
(Date:3/23/2017)... 2017 On Wednesday, March ... session at 5,821.64, up 0.48%; the Dow Jones ... 20,661.30; and the S&P 500 closed at 2,348.45, ... six out of nine sectors ended the day ... coverage on the following Medical Instruments & Supplies ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
Breaking Medicine Technology:
(Date:3/23/2017)... Scottsdale, AZ (PRWEB) , ... March 23, 2017 , ... ... helping people around the world to manage stress and anxiety. , “Buzzies change ... Serin, neuropsychologist, inventor and co-founder of Buzzies. , Since its launch date in December ...
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... Square, PA (PRWEB) , ... March 23, 2017 , ... ... days. That means many students are thinking about summer internships , which can ... lack thereof). , The pros at Garden Media Group, a boutique public relations firm ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams & ... This competition was hosted jointly by HSN and Good Housekeeping. , Steven ...
(Date:3/23/2017)... ... March 23, 2017 , ... News Advisory/Interview Opportunity , After ... score a major victory in Europe for public health and the environment and is ... on rigorous scientific research and the overwhelming support of European citizens, the European Union ...
Breaking Medicine News(10 mins):